These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25715421)

  • 21. Oral hypoglycemic drugs for gestational diabetes.
    Greene MF
    N Engl J Med; 2000 Oct; 343(16):1178-9. PubMed ID: 11036125
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents.
    Rosenecker J; Eichler I; Bärmeier H; von der Hardt H
    Pediatr Pulmonol; 2001 Nov; 32(5):351-5. PubMed ID: 11596159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
    Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical experience with Glibenclamide--Daonil.
    Breidahl HD
    Aust N Z J Med; 1971 Aug; 1():Suppl 2:63-6. PubMed ID: 4115559
    [No Abstract]   [Full Text] [Related]  

  • 25. Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China.
    Li X; Xu A; Sheng H; Ting TH; Mao X; Huang X; Jiang M; Cheng J; Liu L
    Pediatr Diabetes; 2018 Mar; 19(2):251-258. PubMed ID: 28791793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of glidiazinamide].
    Pedrazzi F; Bommartini F
    G Gerontol; 1972 May; 20(5):459-67. PubMed ID: 4626363
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparative evaluation of the hypoglycemic effect of the 2d-generation sulfonylurea preparations maninil and diamicron in diabetes mellitus].
    Balabolkin MI; Morozova TP; Zhizhina SA; Levitskaia ZI; Gincherman LE
    Probl Endokrinol (Mosk); 1982; 28(5):9-11. PubMed ID: 6815639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neonatal diabetes mellitus: treatment with sulfonylurea in a preterm born infant].
    Holl RW
    Klin Padiatr; 2009; 221(2):52-3. PubMed ID: 19263321
    [No Abstract]   [Full Text] [Related]  

  • 30. Glibenclamide--experience at Royal Prince Alfred Hospital 1967-70.
    Burns FH
    Aust N Z J Med; 1971 Aug; 1():Suppl 2:67-71. PubMed ID: 5005133
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapy of diabetes in adults using Glibornurid. Results and clinical studies].
    Schöffling K; Mehnert H; Ewald W; Haupt E; Wicklmayr M; Beyer J; Nemeth N
    Dtsch Med Wochenschr; 1973 May; 98(18):915-9. PubMed ID: 4633717
    [No Abstract]   [Full Text] [Related]  

  • 32. Experience with a new hypoglycemic agent, glibenclamide, HB 419 (Daonil) in diabetes mellitus.
    Ser I
    Isr J Med Sci; 1972 Jun; 8(6):887. PubMed ID: 4626318
    [No Abstract]   [Full Text] [Related]  

  • 33. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
    Loomba-Albrecht LA; Glaser NS; Styne DM; Bremer AA
    Clin Ther; 2009 Apr; 31(4):816-20. PubMed ID: 19446154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
    Marble A
    Drugs; 1971; 1(2):109-15. PubMed ID: 4999930
    [No Abstract]   [Full Text] [Related]  

  • 35. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
    J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 39. Controlled extension of oral antidiabetic therapy on former insulin dependent diabetics by means of the combined i.v. glibenclamide-glucose-response-test.
    Pfeiffer EF; Raptis S
    Diabetologia; 1972 Feb; 8(1):41-7. PubMed ID: 4623790
    [No Abstract]   [Full Text] [Related]  

  • 40. [HB 419 (glibenclamide) and possibilities of its combinations in the treatment of diabetes mellitus].
    Stratmann FW
    Dtsch Med J; 1970 Jan; 21(2):83-7. PubMed ID: 5001692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.